In 2005, two efforts [110,111] highlighted the synthetic lethal interaction between PARP1 inhibition and loss of BRCA1 or BRCA2, which lead to the development of approved clinical PARP inhibitors in ovarian, breast or pancreatic cancer treatments in case of BRCA1 or BRCA2 loss-of-function. This evidence concerns the gene BRCA2 and pancreatic neoplasm.